Literature DB >> 9259745

A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.

.   

Abstract

BACKGROUND AND
PURPOSE: With the approval by the Food and Drug Administration of recombinant tissue plasminogen activator (rt-PA) for acute ischemic stroke within 180 minutes of symptom onset, patients and prehospital and hospital systems will now have to treat stroke as a medical emergency. It is thus critical to develop efficient hospital-based methods for hyperacute stroke patient evaluation and intervention at both community-based and tertiary care academic centers.
METHODS: We describe how the eight centers in the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial developed systems for enrolling patients within 3 hours of symptom onset. The actual methodology and practical sequence of events are detailed. Deming principles of system organization were applied, and each center developed a flowchart of acute stroke patient screening, assessment, and treatment. We divided the process into the following: clinical center background and preparation, screening, stroke team response, data needed before treatment, CT of the head, pharmacy, patient treatment, and monitored care. Critical features, both unique to a given center and shared by several centers (common at four or more centers), were summarized.
RESULTS: Phase I of the trial included several months of preparation with review of every detail involved in the process of acute stroke care at each site. All centers worked closely with emergency medical services. Community stroke awareness and education programs were developed. A stroke team was initiated and worked closely with the emergency department physicians and nurses. Rapid and efficient communication systems and protocols were established to reduce time to complete each task. Standardized stroke examinations and protocols for blood pressure management and intracranial hemorrhage detection as well as nursing flowcharts were used.
CONCLUSIONS: Hyperacute stroke treatment can be initiated, often within 55 minutes of patient arrival at the hospital, in both community and academic settings when all aspects of stroke care processes are identified, streamlined, and built into the day-to-day operations of the prehospital and hospital healthcare delivery system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259745     DOI: 10.1161/01.str.28.8.1530

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  29 in total

Review 1.  Medical therapy for acute ischemic stroke.

Authors:  L B Goldstein
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

2.  Acute Ischemic Stroke.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

3.  [European Stroke Organisation 2008 guidelines for managing acute cerebral infarction or transient ischemic attack. Part 1].

Authors:  P Ringleb; P D Schellinger; W Hacke
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

4.  Discharge destination as a surrogate for Modified Rankin Scale defined outcomes at 3- and 12-months poststroke among stroke survivors.

Authors:  Adnan I Qureshi; Saqib A Chaudhry; Biggya L Sapkota; Gustavo J Rodriguez; M Fareed K Suri
Journal:  Arch Phys Med Rehabil       Date:  2012-03-21       Impact factor: 3.966

5.  The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset.

Authors:  Jeffrey L Saver; Eric E Smith; Gregg C Fonarow; Mathew J Reeves; Xin Zhao; Daiwai M Olson; Lee H Schwamm
Journal:  Stroke       Date:  2010-06-03       Impact factor: 7.914

Review 6.  Management of acute ischaemic stroke in the elderly: tolerability of thrombolytics.

Authors:  D Tanne; D Turgeman; Y Adler
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Too good to treat? Outcomes in patients not receiving thrombolysis due to mild deficits or rapidly improving symptoms.

Authors:  Joshua Z Willey; Joshua Stillman; Juan A Rivolta; Julio Vieira; Margaret M Doyle; Guillermo Linares; Adrian Marchidann; Mitchell S V Elkind; Bernadette Boden-Albala; Randolph S Marshall
Journal:  Int J Stroke       Date:  2011-11-22       Impact factor: 5.266

8.  Thrombolytic therapy for acute ischaemic stroke: what can we do to improve outcomes?

Authors:  Andrew M Demchuk; Simerpreet Bal
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

9.  Frequency, Predictors, and Outcomes of Prehospital and Early Postarrival Neurological Deterioration in Acute Stroke: Exploratory Analysis of the FAST-MAG Randomized Clinical Trial.

Authors:  Kristina Shkirkova; Jeffrey L Saver; Sidney Starkman; Gregory Wong; Julius Weng; Scott Hamilton; David S Liebeskind; Marc Eckstein; Samuel Stratton; Frank Pratt; Robin Conwit; Nerses Sanossian
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

10.  Cerebral Amyloid Angiopathy: A Hidden Risk for IV Thrombolysis?

Authors:  Ryan J Felling; Roland Faigle; Cheng-Ying Ho; Rafael H Llinas; Victor C Urrutia
Journal:  J Neurol Transl Neurosci       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.